Zoetis Inc Stock Price, News & Analysis

Zoetis (NYSE: ZTS) priced $1.75 billion of 0.25% convertible senior notes due 2029, with a $250 million option for additional notes, and expects the offering to close on December 18, 2025. Net proceeds are estimated at approximately $1,723.2 million (or $1,969.6 million if option exercised).

Zoetis intends to use proceeds to fund capped calls (~$163.3 million), purchase ~2.1 million shares for ~$250.3 million now, and repurchase approximately $1.6 billion of common stock (or ~$1.8 billion if option exercised) by Q1 2026.

Key terms: 0.25% coupon, maturity June 15, 2029, initial conversion price ~$148.20 (22.5% premium), cap price for capped calls $211.7150 (75% premium).

Zoetis (NYSE: ZTS) intends to offer $1.75 billion aggregate principal amount of convertible senior notes due June 15, 2029, with an initial purchaser option for an additional $250 million. Net proceeds are expected to fund (i) capped call transactions, (ii) privately negotiated repurchases of common stock and (iii) additional share repurchases to be completed by no later than the first quarter of 2026. Repurchases will be made under the company’s existing $6 billion repurchase program. Capped calls are expected to limit dilution, while option counterparties may hedge by buying or trading Zoetis stock, which could affect market price.

Zoetis (NYSE:ZTS) declared a $0.53 per share dividend for Q1 2026, a 6% increase from the quarterly rate paid in 2025. The dividend is payable on March 3, 2026 to shareholders of record at the close of business on January 20, 2026.

Zoetis (NYSE:ZTS) announced Health Canada approval of Portela (relfovetmab injection) on December 5, 2025, for alleviating pain associated with osteoarthritis (OA) in cats.

Portela is designed to provide three months of OA pain relief from a single injection, targets nerve growth factor (NGF), showed effectiveness in a nine-month field trial in Europe, and was well tolerated including in cats with IRIS stage 1–3 kidney disease. Portela is already approved in the EU and Zoetis anticipates commercial availability in Canada and the EU in 2026.

Zoetis (NYSE: ZTS) hosted an Innovation Webcast on December 2, 2025 to outline its R&D strategy, diversified pipeline and growth catalysts. The company highlighted a 12-candidate pipeline with blockbuster potential, expansion into chronic kidney disease, oncology and cardiology, and a long-term animal health market projected to approach $90 billion by 2035. Zoetis said those therapeutic frontiers plus lifecycle and geographic expansion represent roughly $5 billion in addressable opportunity and underpin its aim to drive sustained revenue growth, profitability and ROIC.

Management participating included CEO Kristin Peck and R&D and finance leaders; the webcast and slides are available on the company investor website with a replay posted after the event.

Zoetis (NYSE: ZTS) announced on November 26, 2025 that the European Commission granted marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs.

Lenivia is described as a long‑acting monoclonal antibody targeting nerve growth factor (NGF) that can reduce OA pain for three months with one injection. A nine‑month field study reported a safety profile with dogs showing increased mobility and decreased pain after one injection. Lenivia will join Librela (bedinvetmab) in Zoetis’ portfolio of OA pain therapies for dogs.

Zoetis (NYSE:ZTS) will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET.

Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to analyst questions. Investors can listen via a live audio webcast at http://investor.zoetis.com/events-presentations, with a replay posted on the Zoetis investor website after the event.

Zoetis (NYSE: ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025 with CEO Kristin Peck, CFO Wetteny Joseph, EVP & President R&D Rob Polzer, and SVP Global Therapeutics Kevin Esch.

The webcast will include pipeline updates, the company’s strategic approach to unmet animal health needs, R&D capabilities, long‑term growth potential, and live Q&A. The release notes that Dr. Esch will succeed Dr. Polzer, effective January 1, 2026.

Investors can access the live webcast and slides via the company investor website, pre‑registration opens today, and a replay will be available after the event.